Wegovy withdrawal symptoms: what actually happens when you stop semaglutide

Does stopping Wegovy cause true withdrawal symptoms?

This is one of the questions our prescribers hear most often, and the short answer is no, not in the way withdrawal works with, say, opioids or benzodiazepines. Semaglutide does not create physical dependence. There is no recognised withdrawal syndrome listed in the NHS patient information for semaglutide, and clinical guidelines do not describe a withdrawal phase after stopping.

What does happen is pharmacological offset. Semaglutide has a half-life of roughly a week, so its concentration in the body falls gradually rather than suddenly. As it clears, the hormonal signals that reduced appetite and slowed gastric emptying fade with it. Hunger returns. Food feels more appealing. Portion sizes that felt comfortable on treatment may feel insufficient. For someone who has been on Wegovy for several months, that shift can feel sharp and confusing, even though it is simply the absence of a drug effect, not the presence of a new one.

Some people also report low mood in the weeks after stopping, and our page on Wegovy withdrawals covers what to expect in more detail. This is not well characterised in trials, and it is worth raising with your prescriber if it happens. The mental health charity Mind is a useful resource if you want independent support while you work through next steps.

How quickly does the appetite come back, and what about weight?

Appetite typically begins returning within days of the last dose. Because semaglutide's half-life means concentration halves each week, the effect is not a cliff edge, but most people notice a meaningful change within two to four weeks of stopping. Cravings that had quietened often resurface. This is biology, not a failure of willpower.

The weight picture is important to understand before stopping. The STEP 1 trial, published in the New England Journal of Medicine, found that participants who stopped semaglutide after 68 weeks regained most of the weight they had lost within the following year, while those who continued maintained their reduction. This is consistent with what clinicians observe: obesity is a long-term condition, and semaglutide treats it for as long as it is taken. Stopping is not a sign of failure, but it is worth going in with realistic expectations about what happens next.

If you are thinking about what happens during a Wegovy pause or stop, the pattern of re-gain is gradual in most cases, which gives time to put other supports in place, dietary changes, activity, or a plan to restart.

Are there any physical symptoms to expect in the first few weeks?

Alongside the return of appetite, some people describe feeling more bloated or noticing that food moves through them differently again, the opposite of the early semaglutide side effects. For some, this transition period brings digestive changes that sit in an uncomfortable middle ground: not the nausea of starting, but not entirely normal either. These tend to settle within a few weeks as the gut adjusts.

Energy levels can dip temporarily. Some people attribute this to eating more (appetite returning before habits have adjusted) rather than to any direct pharmacological effect. Others notice disrupted sleep, particularly if they were sleeping better at a lower weight and have begun to regain some.

Headache and fatigue are reported anecdotally but are not documented as semaglutide-specific discontinuation effects, and if you want a fuller picture you can read about the symptoms of taking Wegovy to understand how the drug behaves across its full course. If you experience anything that concerns you (severe symptoms, significant mood changes, unexpected physical effects) contact a clinician promptly. You can also report suspected medicine effects through the MHRA's Yellow Card scheme.

What are the alternatives to stopping altogether?

For people who are considering stopping because of side effects, cost, or uncertainty about long-term use, stopping completely is not always the only option. Your prescriber may be able to slow the titration pace, hold at a lower dose, take a planned break, or switch approach. Understanding the cost structure of ongoing treatment is often part of that conversation too, particularly if expense is what's prompting the decision.

If you are stopping because you feel your treatment goals have been met, your prescriber can help you plan a structured approach that makes the most of lifestyle changes you have made. A gradual taper rather than an abrupt stop is sometimes discussed, though this is not yet supported by strong published evidence, it is a clinical conversation rather than a protocol. If you started treatment through another provider and are thinking about whether to continue, you can read about megatan semaglutide as one option within the broader semaglutide landscape to help frame the decision. The team at nume's clinical oversight takes this kind of longer-view question seriously.

If you would find it helpful to talk through your specific situation, speaking with our prescribers is a good place to start, no pressure, just a clinical view on where you are and what makes sense.